DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Alex Denner - 4 Alkermes - 3 Susan Langer - 3 Svea Herbst - 3 Bayliss - 3 Sarah Schlesinger - 2 Sarissa - 2 Biogen - 2
Top related locs:
Biogen Alkermes Alzheimer's
Top related orgs:
YORK - 3 Svea - 3 Thomson - 3 Services - 2 Capital - 1 ISS - 1 Alkermes - 1 Capital Management - 1

Search resuls for: "Alex Denner"


4 mentions found


☆ Alkermes wins battle against Sarissa in closely watched boardroom fight
  + stars: | 2023-06-29 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
NEW YORK, June 29 (Reuters) - Alkermes (ALKS.O) beat back activist investor Sarissa Capital Management's boardroom challenge on Thursday when shareholders re-elected all of the biotechnology company's directors in one of the year's most closely watched votes. But investors stuck by the company, which is valued at $5.4 billion, and returned all directors to their seats on the 11-member board. Glass Lewis, ISS's smaller rival, recommended shareholders back all Alkermes directors. Biogen shareholders this week elected Denner's romantic partner, Susan Langer, to fill his seat on the Biogen board after the board had nominated her. Both ISS and Glass Lewis referenced the Biogen matter in their recommendations on how to vote at Alkermes.
Persons: Alkermes, Nancy Wysenski, Sarah Schlesinger, Glass Lewis, Alex Denner, Susan Langer, Schlesinger, Sarissa, Svea Herbst, Bayliss, Chris Reese Organizations: YORK, Capital, Services, ISS, Svea, Thomson Locations: Alkermes, Biogen
☆ Alkermes beats back board room challenge from Sarissa Capital Management, all directors re-elected - sources
  + stars: | 2023-06-29 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +1 min
NEW YORK, June 29 (Reuters) - Shareholders in Alkermes have re-elected all of the biotechnology company's directors, according to two sources familiar with the matter on Thursday, dealing a blow to hedge fund Sarissa Capital Management which pushed to put three candidates on the board. Sarissa, which owns 8.5% of Alkermes, has long criticized the company's stock price and how the biotechnology company is run, and nominated three candidates, including its co-founder, Alex Denner, as director candidates to the 11-member board. But investors in the biotechnology company, which is valued at $5.3 billion, stuck by all incumbents in one of the year's most closely watched proxy contests. Representatives for the company and Sarissa could not be reached for comment. Alkermes had previously refreshed the board with new directors several times in recent years and has had success in developing and bringing new drugs to market.
Persons: Alex Denner, candiates, Sarah Schlesinger, Alkermes, Svea Herbst, Bayliss Organizations: YORK, Alkermes, Capital Management, Services, Svea, Thomson
☆ Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes
  + stars: | 2023-06-14 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
The hedge fund's founder, Alex Denner, 53, one of three Sarissa candidates running for seats on Alkermes' 11-member board, on Monday said he would give up his board seat at biotech company Biogen (BIIB.O). The move eliminates "any claim of conflict whatsoever," Sarissa wrote to Alkermes shareholders on Tuesday. Alkermes shareholders will vote on directors on June 29 in what is one of the year's five biggest boardroom challenges. A Biogen representative confirmed that the board knew about the relationship between Denner and Langer. Denner, who has served on the Biogen board since 2009 and headed the nominating and governance committee, had nominated Langer.
Persons: Alex Denner, Sarissa, Biogen, Susan Langer, Alkermes, Denner, Langer, Bob Langer, Biogen's, Stelios Papadopoulos, Caroline Dorsa, Richard Mulligan, William Jones, Svea Herbst, Bayliss, Bill Berkrot, Mark Porter, Leslie Adler Organizations: YORK, Management, Moderna, Svea, Thomson Locations: Alkermes, Biogen
☆ A 53-year-old biotech investor is set to be replaced by a 32-year-old exec on Biogen's board. No one disclosed that the new board member is his girlfriend and the mother of his child.
  + stars: | 2023-06-13 | by ( Zachary Tracer | ) www.businessinsider.com   time to read: +2 min
The biotech company Biogen is revamping its board of directors. The nominee, Susan Langer, is "highly qualified", Biogen said. Biogen, the $44-billion biotech company known for its work in Alzheimer's, is refreshing its board of directors. Standing for election as a replacement is Susan Langer, a 32-year-old biotech exec and former Biogen employee. Langer, a graduate of Cornell University, is the daughter of the biotech billionaire Robert Langer, known for cofounding Moderna.
Persons: wasn't, Susan Langer, Biogen, Alex Denner, Denner, Langer, Stat, Jack Cox, Ms, Cox, Denner didn't, Langer couldn't, Robert Langer, she's Organizations: Morning, Stat, Board, Stat News, Cornell University, cofounding Moderna, Souffle Therapeutics Locations: Alzheimer's, Biogen
0 next >>
Total: 4